Kaleido Biosciences, Inc. (KLDO)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Feb 12, 2026, 11:05 AM EST
Kaleido Biosciences Company Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.
The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology.
The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen.
Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
Contact Details
Address: 65 Hayden Avenue Lexington, Massachusetts 02421 United States | |
| Phone | 617 674 9000 |
| Website | kaleido.com |
Stock Details
| Ticker Symbol | KLDO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US4833471000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Research & Development and Head of Development |